Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children

•Vi-DT is safe and well tolerated in participants aged 2–45 years.•Significantly higher immune responses post Vi-DT compared to Vi polysaccharide vaccine.•No further increase in GMT post second dose as compared to post first dose of Vi-DT. Typhoid fever remains a major public health problem in low- and middle-income countries where children aged 2–14 years bear the greatest burden. Vi polysaccharide is poorly immunogenic in children